AVTX compared with LBRX: revenue, margins and what each company keeps, and the suppliers and customers both name

AVTXAvalo Therapeutics, Inc.

Mkt capRevenueRevenue

LBRXLB Pharmaceuticals Inc

Mkt capRevenueRevenue

Compare

AVTXAvalo Therapeutics, Inc.

LBRXLB Pharmaceuticals Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

AVTX2 of 4 reports

0 of 2at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±16.8%▼−6.22%×0.37

Q2 FY26±19.6%▼−0.74%×0.04

LBRX

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26thin chain±13.5%▲+10.29%×0.76

Q2 FY26—▼−1.13%—

= impliedAVTX realized, solidLBRX realized, hatchedOne scale, both sides: full bar = 20%× = |realized| ÷ impliedspan: AVTX 91d · LBRX 224dSource: market data

May 13 '26—▲+3.79%—

Q1 FY26—▼−2.81%—

AVTXAvalo Therapeutics, Inc.

6.95▲+4.87%· post 6.95

Mkt cap$400.7MRevenue$59,000Q4 FY25

LBRXLB Pharmaceuticals Inc

42.14▲+10.63%· post 41.17

ClosedNov 6 '26

Mkt cap$1.4BRevenue—

Compare

ClosedNov 6 '26

AVTXAvalo Therapeutics, Inc.

LBRXLB Pharmaceuticals Inc

6.95▲+4.87%post 6.95

Price

42.14▲+10.63%post 41.17

$400.7M

Mkt cap

$1.4B

Q4 FY25$59,000

Revenue

—

AVTX6.95▲+4.87%vsLBRX42.14▲+10.63%ClosedNov 6 '26